GlassScriptPhysician profile
Megan Terrell
NPI 1124724679
$5,986.92
in general payments reported to CMS, 2019-2025
31 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,870 · 2024: $2,272 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,950 · Education: $37.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,949.76 |
| Education | $37.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $875.72 | 2023-2025 | Entyvio, Eohilia |
| Abbvie INC. | $621.93 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $537.59 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $450.76 | 2023-2025 | Stelara, Tremfya |
| Genzyme Corporation | $383.95 | 2023-2025 | |
| Qol Medical, LLC | $383.72 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $355.99 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $334.30 | 2023-2025 | |
| Madrigal Pharmaceuticals | $262.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $247.07 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $244.91 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $205.75 | 2023-2024 | Keytruda, Dificid |
| Ironwood Pharmaceuticals, INC | $125.13 | 2023-2024 | Linzess |
| Lilly USA, LLC | $120.17 | 2023-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $114.51 | 2024-2025 | Iqirvo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $83.16 | 2023-2025 | Gimoti |
| Celltrion USA INC. | $66.34 | 2024-2025 | Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $65.77 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $60.30 | 2023-2025 | Ocaliva |
| Pfizer INC. | $59.52 | 2024-2025 | |
| Shield Therapeutics INC | $58.45 | 2023-2025 | Accrufer |
| Nestle Healthcare Nutrition INC. | $52.29 | 2023 | |
| Celgene Corporation | $49.82 | 2023-2024 | Zeposia |
| Fresenius Kabi USA, LLC | $47.90 | 2023-2024 | Idacio |
| Amgen INC. | $46.46 | 2024-2025 | Uplizna |
| Exact Sciences Corporation | $30.29 | 2023-2024 | Cologuard Collection Kit |
| Enterra Medical, INC. | $23.70 | 2024 | |
| Janssen Scientific Affairs, LLC | $23.46 | 2024 | Stelara |
| Novo Nordisk INC | $19.53 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $18.97 | 2023 | Sutab |
| Axonics, INC. | $16.55 | 2024 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Terrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.